Novavax reported $233.31M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Adma Biologics USD 203.84M 567K Jun/2026
Agenus USD 35.54M 2.34M Mar/2025
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Cassava Sciences USD 0 0 Dec/2024
Geron USD 122.14M 78K Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
MannKind USD 330.85M 112K Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.29B 11M Jun/2026
Novartis USD 48.31B 1.31B Sep/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 62.67B 523M Sep/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
TG Therapeutics USD 754.37M 68K Sep/2026